Noile-Immune Biotech Inc. (TYO:4893)
Japan · Delayed Price · Currency is JPY 137.00
-2.00 (-1.44%)
Jul 16, 2026, 10:04 AM JST
Noile-Immune Biotech Revenue
Noile-Immune Biotech had revenue of 3.00M JPY in the twelve months ending March 31, 2026, down -57.14% year-over-year. In the year 2025, Noile-Immune Biotech had annual revenue of 5.00M, down -28.57%.
Revenue (ttm)
3.00M
Revenue Growth
-57.14%
P/S Ratio
2,010.83
Revenue / Employee
130.43K
Employees
23
Market Cap
6.03B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 5.00M | -2.00M | -28.57% |
| Dec 31, 2024 | 7.00M | -309.00M | -97.78% |
| Dec 31, 2023 | 316.00M | -309.00M | -49.44% |
| Dec 31, 2022 | 625.00M | 525.00M | 525.00% |
| Dec 31, 2021 | 100.00M | 3.00M | 3.09% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Soiken Holdings | 4.40B |
| CellSource | 3.67B |
| MEDINET | 998.00M |
| OncoTherapy Science | 808.00M |
| PRISM BioLab Co.,LTD | 711.65M |
| Carna Biosciences | 619.35M |
| Chiome Bioscience | 601.75M |
| D. Western Therapeutics Institute | 305.97M |